Revolutionary cancer blood test will speed up diagnosis and help cut NHS backlog trends now

Revolutionary cancer blood test will speed up diagnosis and help cut NHS backlog trends now
Revolutionary cancer blood test will speed up diagnosis and help cut NHS backlog trends now

Revolutionary cancer blood test will speed up diagnosis and help cut NHS backlog trends now

Revolutionary cancer blood test will speed up diagnosis and help cut NHS backlog — while drug that slashes chances of breast cancer is returning NHS trial found the 'Galleri' blood test detected two out of every three cancers The test pinpointed where cancer was in 85 per cent of cases of 5000 people

View
comments

A blood test for cancer could be given by GPs to speed up diagnoses and reduce NHS backlogs, world-first data suggests.

An NHS trial found the Galleri blood test revealed two out of every three cancers among 5,000 people who had visited their GP with suspected symptoms.

Where cancer was correctly detected, the test was able to pinpoint where the primary cancer was in 85 per cent of cases.

Experts said the findings, due to be presented at a global conference today, showed scientists were a step closer to an oncology test in GP surgeries.

Developed by bio-technology company Grail, the test looks for tiny fragments of tumour DNA circulating in the bloodstream.

An NHS trial found the Galleri blood test revealed two out of every three cancers among 5,000 people who had visited their GP with suspected symptoms

An NHS trial found the Galleri blood test revealed two out of every three cancers among 5,000 people who had visited their GP with suspected symptoms

Drug that slashes chances of breast cancer returning

A drug can slash the chances of the most common type of breast cancer returning by a quarter, research shows.

Patients who took ribociclib alongside hormone therapy after traditional treatments were significantly less likely to see their cancer return.

The drug targets proteins that help cancer cells multiply, prohibiting growth.

The benefits were seen in patients whose breast cancer had been caught early. Experts said the findings could change practices and reduce worry for patients.

Known as Kisqali, the drug is given to extend the lives of patients whose disease has spread. But the trial tested if it could be effective at preventing cancer returning.

Overall, the addition of ribociclib reduced the risk of recurrence by 25 per cent, the American Society of Clinical Oncology conference in Chicago heard yesterday.

Advertisement

It alerts

read more from dailymail.....

NEXT No wonder you can't get an NHS dentist appointment! Outrage as taxpayer-funded ... trends now